

The actual incidence of Small for Gestational Age (SGA) newborns and their catch-up growth is dramatically lower than previously considered.

Eran Lavi¹, Asher Shafrir¹, Rana Halloun¹ Smadar Eventov Friedman², Abdulsalam Abu Libdeh¹, Hanna Shoob³, Chen Stein-Zamir³ David Haim Zangen¹

- 1. Division of Pediatric Endocrinology, Hadassah, Hebrew University Medical Center.
- 2. Department of Neonatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 3. Jerusalem district health office, ministry of health. The Hebrew University, Hadassah, Jerusalem.

Introduction

The incidence of small for gestational age (SGA) births (weight < 2SD from the mean) varies among populations with an estimate of 10% of term infants in developed countries compared with 10-30% of term infants in developing countries (Figures 1,2). Infants born SGA are at increased risk of perinatal morbidity and mortality, developmental disabilities metabolic alterations (diabetes mellitus type 2, hypertension and hyperlipidemia) in later life and tendency for persistent short stature.




Fig 1. Estimated prevalence of SGA births in 138 low-income and middleincome countries (Lee, Anne CC, et al.)




Fig 2. Incidence of infants born SGA Hospital in Chieti (Valentina Chiavaroli et al)

Catch up growth (CUG) is the accelerated growth during the first years of life achieving a height of more than 2 or 2.5 SD below the mean for age and sex. The incidence of CUG among SGA infants varies significantly in different populations but 85-90% of SGA infants experience CUG (Fig 3). These children are eligible for growth hormone (GH) therapy to increase their final height (Fig 4).




Fig 3. Catch up growth by age 2 years (Karlberg, Pediatric Research 1996)




Fig 4. Growth response to GH therapy in SGA pts. (Boguszewski Acta Paediatrica 1998)

Based on the reported incidence of SGA (5-10%) and CUG failure (10%) in the first two years, we encountered unexpected lower demand for growth hormone therapy for this population. This finding triggered us to survey the actual incidence of SGA and failure in CUG.

Objectives: Finding the actual incidence of SGA infants and their failure in CUG.

Methods


Our cohort included the registry of all-43,307 live babies born at Hadassah hospitals between 2008-2011. SGA was defined according to the 2005 Dolberg's (birth weight<2SD) table for Israeli newborns (similar to WHO parameters). Our calculated weight percentiles birth compared were nationally/internationally used percentile data (NUPD). Follow-up measurements of height and weight were obtained in mother and child centers or at the pediatrician.


References

- J. KARLBERG et al. Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatric research:1995;38:733 -9 Albertsson-Wikland K, Wennergren G, Wennergren M, Vilbergsson G, Rosberg S: Longitudinal follow-up of growth in children born small for gestational age. Acta
- Paediatr 1993;82:438-443 Lee, Anne CC, et al. "National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010." The Lancet Global Health 1.1 (2013): e26-e36.
- 4. Shaul Dollberg, et al. Birth Weight Standards in the Live-Born Population in Israel IMAJ 2005: 7: May: 311-314 5. Wollmann, Hartmut A.. "Intrauterine Growth Restriction: Definition And Etiology." Hormone Research 49. Suppl. 2 (1998): 1-6.
- 6. Chiavaroli V. et al: "Incidence of infants born small- and large-for-gestational-age in an Italian cohort over a 20-year period and associated risk factors.": Ital J Pediatr. 2016 Apr 26;42:42.
- 7. Boguszewski, M., S. Rosberg, and K. Albertsson-Wikland. "Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children." The
- Journal of clinical endocrinology and metabolism 80.9 (1995): 2599-2606.

Results

Out of 43,307 live births at the study hospitals only 524 babies (1.2%) were SGA (52% of expected- Fig 5) approximately 132 out of each 10,000 births. This finding was repeated in every one of the four consecutive years that were examined. Birth weight percentile comparisons showed that 1st and 5th percentile weights in our cohort were significantly (20%) higher while the 95th and 99th percentiles were 5% lower than the NUPD.








Fig 5. SGA incidence in the study population compared to expected data

CUG parameters (available for 447/524 SGA) indicated that 427 (95.7%) had CUG (height >2.5 SD below the mean: Table 2). CUG rate among term SGA infants was even higher (Fig 7). When catch up growth was defined as a standardized height that is greater than -2.0 (SD) 91.3% of the children performed adequately catch up growth (Table 2, Fig 6).




Table 2. CUG prevalence in SGA children (The numbers in parentheses indicate no. of patients)




Fig 6. CUG prevalence in SGA children




Fig 7. CUG prevalence among term and pre term infants




Fig 8. Growth trends over time in SGA children

Conclusions

- The actual number of SGA newborns is nearly half of the expected according to the current WHO/NUPD criteria- only 1.2%.
- The incidence of infantile CUG in SGA infants reaches 95.7%, significantly higher than in previously reported series.
- This study redefines the incidence and the growth pattern of SGA children and should influence the postnatal preventive care practices and complications management of this high risk population.
- Given the impact of our data on health cost planning and GH requirements in SGA babies, it is recommended that similar large European and American cohorts will be conducted to re-determine the incidence of SGA births, catch up growth and standard deviations amplitudes.



